Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318676 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT06318676: Completed Phase 1 study of Renal Impairment, sponsored by Celgene.
NCT06318676 is a Phase 1 study of Renal Impairment that has completed, run by Celgene. The registered enrollment target is 26 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (24% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06318676, a Phase 1 study of Renal Impairment, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
Conditions Studied
Interventions
- DRUG Mezigdomide
Study Locations (3)
Florida
- PANAX - Miami Lakes
- Omega Research Group - Orlando - Orlando
- Orlando Clinical Research Center OCRC - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
What the finished NCT06318676 record still lists
NCT06318676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Mezigdomide is the first listed.
NCT06318676 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06318676 about?
NCT06318676 is a clinical study titled "A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment". The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
What is the current status of trial NCT06318676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-03-21. Estimated completion is 2024-11-15.
What conditions does trial NCT06318676 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT06318676?
The interventions under investigation include: Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT06318676?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318676 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06318676's enrollment target sits among peer trials
26 20th of 32 higher than 13 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI